Older Men Are as Responsive as Young Men to the Anabolic Effects of Graded Doses of Testosterone on the Skeletal Muscle
The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Abstract
Although testosterone levels and muscle mass decline with age, many older men have serum testosterone level in the normal range, leading to speculation about whether older men are less sensitive to testosterone. We determined the responsiveness of androgen-dependent outcomes to graded testosterone doses in older men and compared it to that in young men. The participants in this randomized, double-blind trial were 60 ambulatory, healthy, older men, 60-75 yr of age, who had normal serum testosterone levels. Their responses to graded doses of testosterone were compared with previous data in 61 men, 19-35 yr old. The participants received a long-acting GnRH agonist to suppress endogenous testosterone production and 25, 50, 125, 300, or 600 mg testosterone enanthate weekly for 20 wk. Fat-free mass, fat mass, muscle strength, sexual function, mood, visuospatial cognition, hormone levels, and safety measures were evaluated before, during, and after treatment. Of 60 older men who were randomized, 52 completed the study. After adjusting for testosterone dose, changes in serum total testosterone (change, -6.8, -1.9, +16.1, +49.5, and +101.9 nmol/liter at 25, 50, 125, 300, and 600 mg/wk, respectively) and hemoglobin (change, -3.6, +9.9, +20.9, +12.6, and +29.4 g/liter at 25, 50, 125, 300, and 600 mg/wk, respectively) levels were dose-related in older men and significantly greater in older men than young men (each P < 0.0001). The changes in FFM (-0.3, +1.7, +4.2, +5.6, and +7.3 kg, respectively, in five ascending dose groups) and muscle strength in older men were correlated with testosterone dose and concentrations and were not significantly different in young and older men. Changes in fat mass correlated inversely with testosterone dose (r = -0.54; P < 0.001) and were significantly different in young vs. older men (P < 0.0001); young men receiving 25- and 50-mg doses gained more fat mass than older men (P < 0.0001). Mood and visuospatial cognition did not change significantly in either group. Frequency of hematocrit greater than 54%, leg edema, and prostate events were numerically higher in older men than in young men. Older men are as responsive as young men to testosterone's anabolic effects; however, older men have lower testosterone clearance rates, higher increments in hemoglobin, and a higher frequency of adverse effects. Although substantial gains in muscle mass and strength can be realized in older men with supraphysiological testosterone doses, these high doses are associated with a high frequency of adverse effects. The best trade-off was achieved with a testosterone dose (125 mg) that was associated with high normal testosterone levels, low frequency of adverse events, and significant gains in fat-free mass and muscle strength.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are conflicting data on the effect of testosterone supplementation on muscle strength and function50,51,357,414.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [414]
In the citing paper
“Testosterone has a dose-dependent impact on fat-free mass in both the young and old, with higher levels associated with reduction in fat mass and increase in skeletal muscle mass and strength [43].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [43]
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationAging of skeletal muscle: a 12-yr longitudinal study
Frontera, W. R., Hughes, V. A., Fielding, R. A., Fiatarone, M. A., Evans, W. J., & Roubenoff, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1321 · Cited by 1,443
GRAY, A., FELDMAN, H. A., MCKINLAY, J. B., & LONGCOPE, C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1016 · Cited by 1,118
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · cited 7×
“The characteristics of young men have been described previously (29).”
BackgroundMethodResultInfluentialSelf-citationTestosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.6.1661 · Cited by 922
Hughes, V. A., Frontera, W. R., Wood, M., Evans, W. J., Dallal, G. E., Roubenoff, R., & Singh, M. A. F. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.5.b209 · Cited by 921
Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women
Iannuzzi-Sucich, M., Prestwood, K. M., & Kenny, A. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.12.m772 · Cited by 890
Morley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., Morley, P. M. K., Stauber, P. M., Vellas, B., Baumgartner, R. N., & Garry, P. J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90057-3 · Cited by 830
Cited by
Items 201–300 of 554
Do androgens play any role in the physical frailty of ageing men?
O’Connell, M. D. L., Tajar, A., Roberts, S. A., & Wu, F. C. W. (2010) · International Journal of Andrology · doi:10.1111/j.1365-2605.2010.01093.x · Cited by 49
Yuen, F., Thirumalai, A., Pham, C., Swerdloff, R. S., Anawalt, B. D., Liu, P. Y., Amory, J. K., Bremner, W. J., Dart, C., Wu, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa032 · Cited by 51
Genomic predictors of testosterone levels are associated with muscle fiber size and strength
Guilherme, J. P. L. F., Semenova, E. A., Borisov, O., Larin, A. K., Moreland, E., Generozov, E. V., & Ahmetov, I. I. (2021) · European Journal of Applied Physiology · doi:10.1007/s00421-021-04851-w · Cited by 38
Doping and musculoskeletal system: short‐term and long‐lasting effects of doping agents
Nikolopoulos, D., Spiliopoulou, C., & Theocharis, S. E. (2010) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00881.x · Cited by 61
Haring, R., Travison, T. G., Bhasin, S., Vasan, R. S., Wallaschofski, H., Davda, M. N., Coviello, A. D., & Murabito, J. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1068 · Cited by 37
Self-citationChu, L., Tam, S., Kung, A. W. C., Lo, S., Fan, S., Wong, R. L. C., Morley, J. E., & Lam, K. S. L. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01746.x · Cited by 37
“In previous randomized, controlled clinical trials, testosterone supplementation in men resulted in a consistent increase in muscle strength in hypogonadal and eugonadal older men.(27,28) A recent meta-analysis of major randomized, controlled trials of androgen treatment and muscle strength in elderly men also confirm…”
BackgroundOsteosarcopenic Obesity Associated with Poor Physical Performance in the Elderly Chinese Community
Ma, Y., Zhang, W., Han, P., Kohzuki, M., & Guo, Q. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s257739 · Cited by 44
Chasland, L. C., Yeap, B. B., Maiorana, A., Chan, Y. X., Maslen, B. A., Cooke, B. R., Dembo, L. G., Naylor, L. H., & GREEN, D. J. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00010.2021 · Cited by 46
Bhasin, S., Krishnan, V., Storer, T. W., Steiner, M., & Dobs, A. S. (2023) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glad027 · Cited by 36
Self-citationAn evolutionary and life history perspective on human male reproductive senescence
Bribiescas, R. G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05524.x · Cited by 38
How hormones mediate trade-offs in human health and disease
Bribiescas, R. G., & Ellison, P. T. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199207466.003.0007 · Cited by 40
A physiological role for androgen actions in the absence of androgen receptor DNA binding activity
Pang, T. P. S., Clarke, M. V., Ghasemzadeh, A., Lee, N. K. L., Davey, R. A., & MacLean, H. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.017 · Cited by 37
“Androgens also have anabolic actions in non-reproductive tissues, including increasing muscle strength and bone mineral density (Brill et al., 2002; Bhasin et al., 2005).”
Identification of late-onset hypogonadism in middle-aged and elderly men from a community of China
Sun, Y., Liu, Z., Zhou, R., Lü, X., Zeng, Q., Wang, H., & Li, Z. (2015) · Asian Journal of Andrology · doi:10.4103/1008-682x.160883 · Cited by 37
Storer, T. W., Bhasin, S., Travison, T. G., Pencina, K. M., Miciek, R., McKinnon, J., & Basaria, S. S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4333 · Cited by 36
Self-citationLeBrasseur, N. K., Lajevardi, N., Miciek, R., Mazer, N., Storer, T. W., & Bhasin, S. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2008.10.005 · Cited by 34
“To address this issue, the TOM study will employ a reliable and proven method for measuring dynamic muscle strength that the investigative team has used in older individuals [36] and shown to be androgen-resposnive [23]; the leg press 1RM.”
BackgroundMethodSelf-citationEvaluation of early biomarkers of muscle anabolic response to testosterone
Chen, F., Lam, R., Shaywitz, D., Hendrickson, R., Opiteck, G., Wishengrad, D., Liaw, A., Song, Q., Stewart, A. J., Cummings, C. E., et al. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0021-y · Cited by 34
“Because older men may experience more side effects from higher doses of testosterone [6], the 600-mg testosterone dose was only administered to younger men (18–40 years old) in study 2.”
BackgroundSelf-citationStephens‐Shields, A. J., Snyder, P. J., Ellenberg, S. S., Taylor, L., & Bhasin, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac028 · Cited by 37
Self-citationFukui, M., Tanaka, M., Hasegawa, G., Yoshikawa, T., & Nakamura, N. (2008) · Diabetes Care · doi:10.2337/dc07-1898 · Cited by 38
Dent, J. R., Fletcher, D. K., & McGuigan, M. R. (2012) · Europe PMC (PubMed Central) · Cited by 50
Badawy, A. A. ‐. (2018) · International Journal of Tryptophan Research · doi:10.1177/1178646917753422 · Cited by 36
Influence of Androgens on Circulating Adiponectin in Male and Female Rodents
Yarrow, J. F., Beggs, L. A., Conover, C. F., McCoy, S. C., Beck, D. T., & Borst, S. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047315 · Cited by 37
“In particular, previous reports indicate that testosterone lowers total adiponectin within the circulation [6,13,17,18,34], which is surprising given the known lipolytic [11,15,16] and insulin”
BackgroundInfluentialAndrogens, angiogenesis and cardiovascular regeneration
Sieveking, D. P., Chow, R., & Ng, M. K. C. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283394e20 · Cited by 34
Roberts, M. D., Dalbo, V. J., Hassell, S. E., & Kerksick, C. M. (2009) · The Journal of Strength and Conditioning Research · doi:10.1519/jsc.0b013e3181a59bdd · Cited by 34
“(5,30) have performed a series of clinical trials demonstrating that administering superphysiological doses of testosterone to younger and older men significantly increases lean body mass and lower-body strength, as well as serum-free testosterone, satellite cell number, and muscle fiber cross-sectional area.”
BackgroundMass spectrometry of hydantoin‐derived selective androgen receptor modulators
Thevis, M., Kohler, M., Schlörer, N. E., Kamber, M., Kühn, A., Linscheid, M. W., & Schänzer, W. (2007) · Journal of Mass Spectrometry · doi:10.1002/jms.1364 · Cited by 32
Hamann, L. G., Manfredi, M. C., Sun, C., Krystek, S. R., Huang, Y., Bi, Y., Augeri, D. J., Wang, T., Zou, Y., Betebenner, D. A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.076 · Cited by 35
Handelsman, D. J. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.09.005 · Cited by 36
Ullrich, T., Sasmal, S., Boorgu, V., Pasagadi, S., Cheera, S., Rajagopalan, S., Bhumireddy, A., Shashikumar, D., Chelur, S., Belliappa, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5009049 · Cited by 32
Handelsman, D. J., Idan, A., Grainger, J., Goebel, C., Turner, L., & Conway, A. J. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.01.011 · Cited by 31
Tapper, J., Arver, S., Pencina, K. M., Martling, A., Blomqvist, L., Buchli, C., Li, Z., Gagliano‐Jucá, T., Travison, T. G., Huang, G. T.-W., et al. (2017) · Andrology · doi:10.1111/andr.12454 · Cited by 31
“These doses were based on dose–response studies in healthy men (Bhasin et al., 2001, 2005).”
BackgroundMethodResultSelf-citationAndrogen Deficiency in Aging and Metabolically Challenged Men
Shelton, J. B., & Rajfer, J. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.09.007 · Cited by 32
Androgens and male aging: current evidence of safety and efficacy
Gooren, L. J. (2010) · Asian Journal of Andrology · doi:10.1038/aja.2010.4 · Cited by 30
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism
Huhtaniemi, I. T., & Wu, F. C. W. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101622 · Cited by 31
Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
Traish, A. M. (2016) · Korean journal of urology · doi:10.4111/icu.2016.57.6.384 · Cited by 33
“Additional evidence is surmised from studies in which T therapy in men with medically induced TD results in a dosedependent increase in muscle mass and reduction in FM in young and elderly men [79].”
BackgroundYao, J., Wang, Y., Yang, L., Ren, M., Li, L., & Wang, H. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-067425 · Cited by 33
Nelson, N. R., Bird, I. M., & Behan, M. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2010.198200 · Cited by 26
“This population has been shown to be as responsive as younger men to the anabolic effects of high, physiological doses of supplemental testosterone on skeletal muscle (Bhasin et al. 2005).”
BackgroundHypogonadism in male outpatients with sarcoidosis
Spruit, M. A., Thomeer, M., Gosselink, R., Wuyts, W. A., Herck, E. V., Bouillon, R., Demedts, M., & Decramer, M. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.07.009 · Cited by 29
Ipulan, L. A., Suzuki, K., Sakamoto, Y., Murashima, A., Imai, Y., Omori, A., Nakagata, N., Nishinakamura, R., Valášek, P., & Yamada, G. (2014) · Endocrinology · doi:10.1210/en.2014-1008 · Cited by 29
Disuse Atrophy of Human Skeletal Muscle: Cell Signaling and Potential Interventions
Urso, M. L. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181a6458a · Cited by 33
Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome
Tolrà, J. R., Barreda, J. T., del Río, L., Gregorio, S. D., & Miranda, E. F. (2013) · The Aging Male · doi:10.3109/13685538.2013.839648 · Cited by 28
“The authors found that the two groups responded equally well to testosterone treatment [13].”
BackgroundThirumalai, A., Cooper, L. A., Rubinow, K. B., Amory, J. K., Lin, D. W., Wright, J. L., Marck, B. T., Matsumoto, A. M., & Page, S. T. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1483 · Cited by 29
“Our results are consistent with previous work demonstrating that healthy older men undergoing medical castration followed by im T administration exhibit dose-dependent effects on hemoglobin but not PSA, suggestingthat thenonlinearresponseof intraprostaticandrogensto serum T we report here using transdermal gel may be…”
ResultAjo, R., Segura, A., Mira, L., Inda, M., Alfayate, R., Sánchez-Barbie, Á., Margarit, C., & Peiró, A. M. (2016) · The Aging Male · doi:10.1080/13685538.2016.1185408 · Cited by 28
Role of testosterone in cognition and mobility of aging men
Kaufman, J., & Lapauw, B. (2020) · Andrology · doi:10.1111/andr.12872 · Cited by 32
Lisco, G., Giagulli, V. A., Tullio, A. D., Pergola, G. D., Guastamacchia, E., & Triggiani, V. (2020) · Geriatrics · doi:10.3390/geriatrics5040076 · Cited by 29
“These ameliorations were specifically found in the case of a remarkable T supplementation, while they become negligible in the case of a mild supplementation by means of T gel 1%, T undecanoate 160 mg/d, T enanthate (50–600 mg/w) [60,65,69,71,72].”
BackgroundTestosterone Replacement Therapy and BPH/LUTS. What is the Evidence?
Baas, W., & Köhler, T. (2016) · Current Urology Reports · doi:10.1007/s11934-016-0600-8 · Cited by 29
Testosterone prevents protein loss via the hepatic urea cycle in human
Lam, T., Poljak, A., McLean, M. P., Bahl, N., Ho, K. K. Y., & Birzniece, V. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0868 · Cited by 29
Hepatic actions of androgens in the regulation of metabolism
Birzniece, V. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000405 · Cited by 33
Evolution, developmental plasticity, and metabolic disease
Kuzawa, C. W., Gluckman, P. D., Hanson, M. A., & Beedle, A. S. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199207466.003.0019 · Cited by 30
Serum testosterone levels correlate with haemoglobin in middle‐aged and older men
Yeap, B. B., Beilin, J., Shi, Z., Knuiman, M. W., Olynyk, J. K., Bruce, D. G., & Milward, E. A. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01789.x · Cited by 29
Fitts, R. H., Peters, J. R., Dillon, E. L., Durham, W. J., Sheffield-Moore, M., & Urban, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2759 · Cited by 26
Simão, V. A., Belardin, L. B., Leite, G. A. A., Chuffa, L. G. D. A., & Camargo, I. C. C. (2015) · International Journal of Experimental Pathology · doi:10.1111/iep.12144 · Cited by 26
“Doses of 1.87 and 3.75 mg ND/kg were used to evaluate the effects of doses employed in various treatments (ranging from 50 to 200 mg/week; Evans 1997) or lowest doses than physiologic replacement doses (ranging from 25 to 600 mg/week; Bhasin et al. 2005).”
MethodInfluentialLifestyle, diet, and disease: comparative perspectives on the determinants of chronic health risks
Leonard, W. R. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199207466.003.0020 · Cited by 35
Chimento, A., Sirianni, R., Zolea, F., Luca, A. D., Lanzino, M., Catalano, S., Andò, S., & Pezzi, V. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22936 · Cited by 29
“Since muscle mass and strength are correlated with the administered dose and the circulating concentrations of AAS (Bhasin et al., 2001, 2005), the doses commonly used in practice are extremely high and range from 500 to 1,000mg/weekly (Pope and Katz, 1994; Evans, 1997a).”
BackgroundAndrogen interacts with exercise through the mTOR pathway to induce skeletal muscle hypertrophy
Zeng, F., Zhao, H., & Liao, J. (2017) · Biology of Sport · doi:10.5114/biolsport.2017.69818 · Cited by 27
Current Status of Sarcopenia in Korea: A Focus on Korean Geripausal Women
Park, H. M. (2018) · Annals of Geriatric Medicine and Research · doi:10.4235/agmr.2018.22.2.52 · Cited by 26
Tapper, J., Huang, G. T.-W., Pencina, K. M., Li, Z., Arver, S., Martling, A., Blomqvist, L., Buchli, C., Travison, T. G., Storer, T. W., et al. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001410 · Cited by 27
Self-citationAdvances in male hormone substitution therapy
Qoubaitary, A., Swerdloff, R. S., & Wang, C. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.9.1493 · Cited by 26
“In patients with decompensated congestive heart failure, supraphysiological doses of testosterone may cause acute fluid retention, which aggravates the symptoms [24,49].”
BackgroundHormones and health outcomes in aging men
Yeap, B. B. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.07.012 · Cited by 30
Physiological basis behind ergogenic effects of anabolic androgens
Cheung, A. S., & Grossmann, M. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.047 · Cited by 34
Wu, B. W., Lorezanza, D., Badash, I., Berger, M., Lane, C. J., Sum, J. C., Hatch, G. F. R., & Schroeder, E. T. (2017) · Orthopaedic Journal of Sports Medicine · doi:10.1177/2325967117722794 · Cited by 28
Androgen Physiology, Pharmacology, and Abuse
Handelsman, D. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00137-4 · Cited by 31
Meikle, A. W. (2006) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70456-6 · Cited by 24
Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge
Gild, M. L., Stuart, M. C., Clifton-Bligh, R. J., Kinahan, A., & Handelsman, D. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac223 · Cited by 30
GREEN, D. J., Chasland, L. C., Yeap, B. B., & Naylor, L. H. (2024) · Sports Medicine - Open · doi:10.1186/s40798-024-00703-x · Cited by 34
“Given that T intervention studies employ a range of doses, Bhasin et al. [56] used a long-acting gonadotropin-releasing hormone agonist to suppress endogenous T secretion and assessed responses to five different doses of T (ranging from 25 to 600 mg/wk) over five months to determine T dose–response…”
BackgroundMethodResultInfluentialIdentification of serum biomarkers for aging and anabolic response
Banerjee, C., Ulloor, J., Dillon, E. L., Dahodwala, Q. A., Franklin, B., Storer, T. W., Sebastiani, P., Sheffield‐Moore, M., Urban, R. J., Bhasin, S., et al. (2011) · Immunity & Ageing · doi:10.1186/1742-4933-8-5 · Cited by 29
“For more in depth description of enrollment criteria and physical function, see Bhasin et al, in [11,13].”
BackgroundMethodInfluentialSelf-citationObesity, Body Composition, and Sex Hormones: Implications for Cardiovascular Risk
Singh, P., Covassin, N., Marlatt, K. L., Gadde, K. M., & Heymsfield, S. B. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210014 · Cited by 56
Traish, A. M. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00174.2016 · Cited by 26
Scientific overview of hormone treatment used for rejuvenation
Morley, J. E. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.04.009 · Cited by 25
Mechanisms of Testosterone's Anabolic Effects on Muscle and Function: Controversies and New Insights
Bhasin, S., Wang, C., Chandra, M. R. G., Gagliano‐Jucá, T., & Jasuja, R. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf041 · Cited by 32
Self-citationTestosterone, frailty and physical function in older men
Hsu, B., Cumming, R. G., & Handelsman, D. J. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1475227 · Cited by 25
Working Group on Functional Outcome Measures for Clinical Trials (2009) · The Journals of Gerontology Series A · doi:10.1093/gerona/gln042 · Cited by 23
Wu, F., Zitzmann, M., Heiselman, D., Donatucci, C., Knorr, J., Patel, A. B., & Kinchen, K. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.05.010 · Cited by 21
Androgens and prostate disease
Page, S., & Cooper, L. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122361 · Cited by 30
“Consistent with these results, Bhasin et al (59) showed that in 60 older men treated with a GnRH agonist to suppress endogenous testosterone, and then given back testosterone in dosing ranging from 25-600mg weekly for 20 weeks, there was dose-dependent correlation with T and free fat mass and muscle strength, but not…”
ResultMin, L., Yanase, T., Tanaka, T., Fan, W., Nomura, M., Kawate, H., Okabe, T., Takayanagi, R., & Nawata, H. (2009) · Endocrinology · doi:10.1210/en.2009-0405 · Cited by 23
Testosterone replacement therapy and voiding dysfunction
Baas, W., & Köhler, T. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.08.11 · Cited by 24
“In fact, there are numerous interesting studies that have given men testosterone, even resulting in very high supraphysiologic T levels, which resulted in no change in prostate size (50-54).”
BackgroundThe physiological and pharmacological basis for the ergogenic effects of androgens in elite sports
Choong, K., Lakshman, K. M., & Bhasin, S. (2008) · Asian Journal of Andrology · doi:10.1111/j.1745-7262.2008.00407.x · Cited by 26
Self-citationBuratto, J., Kirk, B., Phu, S., Vogrin, S., & Duque, G. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.013 · Cited by 22
McCoy, S. C., Yarrow, J. F., Conover, C. F., Borsa, P. A., Tillman, M. D., Conrad, B. P., Pingel, J. E., Wronski, T. J., Johnson, S., Kristinsson, H. G., et al. (2012) · Bone · doi:10.1016/j.bone.2012.07.008 · Cited by 22
“Of these, prostate enlargement and prostate/lower urinary tract symptoms are commonly reported side effects of TRT [12,44–47].”
BackgroundAndersen, A. B., Jacobson, G. A., Bejder, J., Premilovac, D., Richards, S. M., Rasmussen, J., Jessen, S., & Hostrup, M. (2021) · Sports Medicine · doi:10.1007/s40279-021-01450-9 · Cited by 26
“But while such effects would seem detrimental for aerobic-dominated performances, testosterone treatment has been shown to stimulate erythropoiesis [173, 184], and it may, therefore, be a question of whether the enhancing effects of AAS on hematological parameters, in addition to muscle power, compensate for a potenti…”
BackgroundTestosterone, Diabetes Risk, and Diabetes Prevention in Men
Yeap, B. B., & Wittert, G. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.004 · Cited by 21
History of androgens and androgen action
Handelsman, D. J. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101629 · Cited by 22
Understanding the development of sarcopenic obesity
Gross, D. C., Cheever, C. R., & Batsis, J. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2267672 · Cited by 21
“Additionally, both younger and older men may similarly be responsive to the anabolic effects of testosterone therapy on muscle growth [166].”
BackgroundSubcellular effects of myocyte-specific androgen receptor overexpression in mice
Musa, M., Fernando, S. M., Chatterjee, D., & Monks, D. A. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0071 · Cited by 19
Zitzmann, M., Cremers, J. F., Krallmann, C., & Kliesch, S. (2022) · The Aging Male · doi:10.1080/13685538.2022.2063830 · Cited by 20
Diagnosis and Treatment of Low Testosterone among Patients with End‐Stage Renal Disease
Bao, Y., & Johansen, K. L. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12318 · Cited by 21
“(30) have previously shown that older men are as responsive as young men to the anabolic effects of testosterone on muscle, and the response is dose dependent.”
BackgroundGrowth and Development during Early Manhood as Determinants of Prostate Size in Later Life
Zhuang, T. N., Ly, L. P., Cumming, R. G., & Handelsman, D. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1214 · Cited by 20
Emergence of new infectious diseases
Woolhouse, M. E. J., & Antia, R. (2007) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199207466.003.0016 · Cited by 23
Testosterone therapy in older men with late-onset hypogonadism: a counter-rationale
Basaria, S. (2013) · Endocrine Practice · doi:10.4158/ep13318.ra · Cited by 18
Certainly More Guidelines than Rules
McLachlan, R. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0838 · Cited by 18
Guilherme, J. P. L. F., Шихова, Ю. В., Дондуковская, Р. Р., Топанова, А. А., Semenova, E. A., Astratenkova, I. V., & Ahmetov, I. I. (2021) · Annals of Human Biology · doi:10.1080/03014460.2021.1919204 · Cited by 18
“Testosterone or precursor androgens (e.g. dihydrotestosterone) exert their physiological effects largely by binding to the androgen receptor (AR), particularly in skeletal muscle (Dubois et al. 2012), where they have a well-known anabolic effect (Bhasin et al. 2001, 2005).”
BackgroundPerformance Enhancing Hormone Doping in Sport
Handelsman, D. J. (2015) · Cited by 20
The role of androgens on periodontal repair in female rats
Steffens, J. P., Santana, L. C. L., Pitombo, J. C. P., Ribeiro, D. O., Albaricci, M. C. D. C., Warnavin, S. V. S. C., Kantarcı, A., & Spolidório, L. C. (2018) · Journal of Periodontology · doi:10.1002/jper.17-0435 · Cited by 19
Chen, Y., Lee, N. K. L., Zajac, J. D., & MacLean, H. E. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346441 · Cited by 19
Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact?
Vis, A. N., van der Sluis, T. M., Al-Itejawi, H. H. M., van Moorselaar, R. J. A., & MEULEMAN, E. J. H. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.04.016 · Cited by 24
Matsumoto, A. M., & Bremner, W. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00019-8 · Cited by 27
Straftis, A. A., & Gray, P. B. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16183261 · Cited by 19
Matsumoto, A. M., & Bremner, W. J. (2011) · Williams Textbook of Endocrinology · doi:10.1016/b978-1-4377-0324-5.00019-5 · Cited by 18
Low Testosterone in Chronic Obstructive Pulmonary Disease
Laghi, F. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2508008 · Cited by 18
Chasland, L. C., Naylor, L. H., Yeap, B. B., Maiorana, A., & GREEN, D. J. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16411 · Cited by 18
dos Santos, M. R., & Storer, T. W. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.012 · Cited by 18
Self-citationLost in translation: challenges of current pharmacotherapy for sarcopenia
Tsai, S. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.05.016 · Cited by 20
Metadata
- Authors
- Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Mac, R. P., Lee, M., Yarasheski, K. E., Sinha-Hikim, I., Dzekov, C., Dzekov, J., Magliano, L., & Storer, T. W.
- Affiliations
- University of California, Los Angeles (US)
- Charles R. Drew University of Medicine and Science (US)
- Washington University in St. Louis (US)
- El Camino College (US)
- Corresponding author
- Bhasin, Shalender
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-02
- Volume
- 90
- Issue
- 2
- Pages
- 678-688
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2133467178
- Cited by
- 544
- References
- 73
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 23 · 2023: 16 · 2022: 30 · 2021: 13 · 2020: 19 · 2019: 17 · 2018: 30 · 2017: 28 · 2016: 17 · 2015: 19 · 2014: 22 · 2013: 29 · 2012: 22
- FWCI
- 28.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p41rr000954-34, 5u01dk054047-06)
- National Institute on Aging (1R01 AG-14369-01, R01AG014369)
- National Institute of General Medical Sciences (GM-00425)
- National Institute of Diabetes and Digestive and Kidney Diseases (1R01 DK 59627-01, U01-DK-54047, R01DK049296, 2R01DK49296-02A, R01DK059627)
- National Center for Research Resources (G12 RR 03026, P41-RR000954, P20RR11145, 5P41-RR-000954, G12RR003026, P20RR011145)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD041748, R01HD043348)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
- Keywords
- older men, androgen response, skeletal muscle, fat-free mass, fat mass, muscle strength, sexual function, mood, visuospatial cognition, GnRH agonist, testosterone replacement therapy, aging, hemoglobin response, adverse effects, treatment discontinuation
- MeSH terms
- Adult, Age Factors, Aged, Aging, Energy Intake, Exercise Test, Humans, Luteinizing Hormone, Male, Middle Aged, Sexual Behavior, Sex Hormone-Binding Globulin, Testosterone, Leuprolide, Muscle, Skeletal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.